FDA Approved: LOPID — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for Lopid (gemfibrozil) submitted by Parke-Davis Div of Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hyperlipidemia
• Hypertriglyceridemia

Drugs mentioned

• LOPID (Gemfibrozil)

Snippet

SUPPL AP for LOPID (GEMFIBROZIL)